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Abstract
Background: The current method of delivering gene replacement to the posterior segment of the eye involves a three-port
pars plana vitrectomy followed by injection of the agent through a 37-gauge cannula, which is potentially wrought with
retinal complications. In this paper we investigate the safety and efficacy of delivering adeno-associated viral (AAV) vector to
the suprachoroidal space using an ab externo approach that utilizes an illuminated microcatheter.
Methods: 6 New Zealand White rabbits and 2 Dutch Belted rabbits were used to evaluate the ab externo delivery method.
sc-AAV5-smCBA-hGFP vector was delivered into the suprachoroidal space using an illuminated iTrackTM 250A
microcatheter. Six weeks after surgery, the rabbits were sacrificed and their eyes evaluated for AAV transfection using
immunofluorescent antibody staining of GFP.
Results: Immunostaining of sectioned and whole-mounted eyes demonstrated robust transfection in all treated eyes, with
no fluorescence in untreated control eyes. Transfection occurred diffusely and involved both the choroid and the retina. No
apparent adverse effects caused by either the viral vector or the procedure itself could be seen either clinically or
histologically.
Conclusions: The ab externo method of delivery using a microcatheter was successful in safely and effectively delivering a
gene therapy agent to the suprachoroidal space. This method presents a less invasive alternative to the current method of
virally vectored gene delivery.
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Introduction
While the field of ophthalmology continues to be revolutionized
by new pharmacologic and biologic treatments, techniques for the
delivery of such therapies have only evolved minimally. Recently,
promising advances have been made in the treatment of Leber’s
congenital amaurosis (LCA)—a rare form of hereditary childhood
blindness—through the use of ocular gene therapy. LCA2 is a
form of recessively inherited retinal blindness caused by mutations
in the RPE65 gene, which is expressed in retinal pigmented
epithelium and codes for a 65-kD protein [1–3]. Without a
functional RPE65 gene, rod and cone photoreceptor cells become
deficient in 11-cis retinal and are unable to respond to light [1].
This results in impaired vision from birth and a deterioration of
vision that results in total blindness by the third or fourth decade of
life [1,2].
Several human trials investigating the use of adeno-associated
virus (AAV) as a vector for transferring wild-type RPE65 into the
retina have demonstrated that such treatments can lead to marked
visual improvements with minimal to no adverse effects [1–5].
Typically, the technique for delivering the vector consists of a
three-port pars plana vitrectomy with subretinal injection of the
viral complex through a 37-gauge cannula [1–3]. In trials
conducted by Maguire, et al. and Simonelli, et al., one of six and
one of three patients respectively developed a macular hole in the
post-operative period [2,5]. In both cases, it was concluded that
the macular hole was likely due to a pre-existing epiretinal
membrane contraction that was stimulated by the surgical
procedure itself rather than the vector [2,5].
This post-operative finding highlights the potential benefits of
ab-externo delivery of gene replacement and other potential
therapeutic agents into the subretinal space. Using the rabbit as an
animal model, we explore the possibility of delivering AAV vector
to the suprachoroidal space using the iTrackTM 250A micro-
catheter. This microcatheter, which was originally designed for use
in the Schlemm’s canal for the treatment of open-angle glaucoma
[6], was later shown to be safe and effective in introducing drugs
into the posterior segment of the eye [7]. Compared to a
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method of delivering therapeutic agents into the eye. For the first
time, our study investigates the safety and effectiveness of
delivering a gene replacement vector through this method.
Materials and Methods
Study Design
Six adult New Zealand White rabbits and two Dutch Belted
rabbits were used in this study. All animal experiments performed
adhered to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research and were approved by the
University of Florida’s Institutional Animal Care and Use
Committee, study number 200801808.
The right eyes of the albino rabbits received vector while the left
eyes were used as untreated controls. Between the two Dutch
Belted rabbits, three pigmented eyes received vector while one was
used as a control.
Vector Delivery
All eyes were dilated and the rabbits were anesthetized with a
35 mg/kg ketamine (‘‘Ketaject’’, Phoenix, MO) and intramuscular
5 mg/kg xylazine (‘‘Xyla-ject’’, Phoenix, MO). A 4–5 mm
superior limbal conjunctival peritomy was performed to expose
bare sclera. A #75 Beaver
TM blade (Becton Dickinson & Co.,
Franklin Lakes, NJ) was used to perform a 1–2 mm radial incision
to expose bare choroid approximately 3–4 mm posterior to the
limbus.
The iTrack
TM 250A microcatheter (provided courtesy of
iScience Interventional, Menlo Park, CA) connected to the
iLumin
TM laser-diode based micro-illumination system (iScience
Interventional, Menlo Park, CA) was then introduced into the
suprachoroidal space and advanced posteriorly toward the optic
disc (Figs. S1 and S2). Using indirect ophthalmoscopy, the
illuminated catheter tip was further manipulated and confirmed
to be at the posterior pole or in the retinal periphery. 100 ml of sc-
AAV5-smCBA-hGFP vector at a concentration of 4.5610
13 vector
genomes/ml (produced as described by Zolotukhin, et al. [8]) was
injected into the potential space. The microcatheter was extracted
and the conjunctiva closed with 8-0 Vicryl suture (Ethicon Inc.,
Somerville, NJ).
The surgical eyes received ciprofloxacin drops at the end of the
case and were examined by indirect ophthalmoscopy at 1, 3, and 6
weeks post-operatively.
Histology
The rabbits were sacrificed at 6 weeks after surgery. The globes
were removed and placed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 24 hrs and then incubated in 30%
sucrose in PBS for cryoprotection. Whole mounts were prepared
for all 4 pigmented rabbit eyes and 8 albino eyes (4 treated, 4
untreated). The remaining 4 albino eyes (2 treated, 2 untreated)
were embedded in Optimum Cutting Temperature (O.C.T.,
Sakura Finetek USA, Torrance, CA) then frozen at 220uC and
cryosectioned at 25 microns.
The sections were immunostained using a mouse anti-GFP
primary antibody (courtesy of Dr. W. Clay Smith, University of
Florida) and Alexa 488 fluorophore secondary antibody (Invitro-
gen, Eugene, OR). Fluorescence was visualized using scanning
confocal microscopy.
Results
In each of the treated eyes, we were able to effectively access
and cannulate the suprachoroidal space. The correct location of
the illuminated cannula tip was confirmed under direct visualiza-
tion. A localized suprachoroidal detachment was observed after
the administration of 100 ml of vector. Two rabbits demonstrated
loss of retinal perfusion during administration indicative of
increased intraocular pressure. This necessitated an anterior
chamber paracentesis with rapid reestablishment of good perfu-
sion. All rabbits tolerated the surgical procedure and anesthesia
without any complication. Subsequent clinical examinations on
post-operative day (POD) 1 demonstrated resolution of the
suprachoroidal detachment without any evidence of retinal
hemorrhage or damage. Further follow-up showed no evidence
of retinal detachment, ocular infection, vitreous hemorrhage, or
other adverse events.
Six weeks following vector delivery, examination of whole-
mounted treated eyes demonstrated robust transfection corre-
sponding to the area of injection-induced suprachoroidal detach-
ment (Fig. 1A). Examination of whole-mounted eyes confirmed an
absence of GFP in controls (Fig. 1B). Efficacy of transfection for
treated eyes appeared similar among all eyes by microscopic
examination of the histological specimen in both NZW and Dutch
Belted rabbits. Although direct staining of the retina and choroid
was not performed, it is believed from the whole mounts (Fig. 2)
and sections (Fig. 3) that GFP transfection occurred at the level of
the choroid, retinal pigmented epithelium (RPE), photoreceptors,
Figure 1. Fluorescent light micrograph of retinal whole mounts, oriented photoreceptors downward. A. Treated right eye of a New
Zealand white rabbit demonstrates immunofluroescence; B. Non-treated left eye of the same rabbit demonstrates lack of immunofluorescence.
doi:10.1371/journal.pone.0017140.g001
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destruction was noted.
Discussion
Considering the recent progress in the treatment of LCA2 and
color blindness using ocular gene therapy [1–5], the successful
delivery of gene-replacement and other therapeutic agents into the
eye has become a potentially important treatment option for many
retinal diseases. While the development of these therapeutic agents
has progressed dramatically, the method for delivering these
products has remained largely unchanged. The standard method
of delivery—a three-port pars plana vitrectomy followed by a
subretinal injection—carries a risk of surgical complications.
Previous trials using this technique to deliver AAV by subretinal
injection of virus following vitrectomy have demonstrated the
possibility of creating a full-thickness macular hole [2,5]. In
addition, Hauswirth, et al. reported the presence of foveal thinning
in one patient [3].
In our study, we were able to safely deliver AAV vector to the
suprachoroidal space in the rabbit model, with no apparent
adverse effects caused by either the viral vector or the procedure
itself. We were also able to show that the vector successfully
delivered the gene product into an injection-induced bleb within
the retina and choroid. Compared to a standard three-port pars
plana vitrectomy with a subretinal injection, the ab-externo
method of vector delivery using the microcatheter is a much
quicker and less invasive procedure with theoretically less risk of
complications to the retina and surrounding tissues. As therapy
moves towards treatment of patients at a younger age, the
advantage of avoiding potential contact with the crystalline lens or
disruption of the hyaloid face may result in this being a much safer
and preferred method of delivery. As surgeons become more
skilled in manipulating the microcatheter, it may be possible to
deliver multiple, targeted treatments to specific areas of the retina
without requiring multiple injections through the retina, as would
be the case with the current vitrectomy technique. Additionally,
even more specific targeting of cell types can be achieved by
Figure 2. Fluorescent light micrographs of choroid in whole mount. A. Intense immunofluorescence seen in treated left eye from a Dutch
Belted rabbit. B. Non-treated left eye showing lack of immunofluorescence.
doi:10.1371/journal.pone.0017140.g002
Figure 3. Fluorsecent light micrographs of retinal cross sections. A. Treated eye of a Dutch Belted rabbit demonstrating
immunofluorescence likely occuring at the level of choroid (C), retinal pigmented epithelium (RPE), photoreceptors (PR), and retinal ganglion
cells (GC). B. Untreated eye of a Dutch Belted rabbit with autofluorescence seen at the level of choroid (C) and retinal pigmented epithelium (RPE).
doi:10.1371/journal.pone.0017140.g003
Suprachoroidal AAV Delivery with Microcatheter
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17140utilizing AAV serotypes with varying tissue tropism and/or tissue
specific promoters [9,10].
A number of potential future uses for this technique are
currently being investigated. Recently, it has been shown that
subretinal injections of AAV can deliver the L-opsin gene to the
photoreceptor layer, restoring trichromatic vision in adult
monkeys effected by red-green colorblindness [10]. However, in
the aforementioned study, successful transfection was localized
only to the areas around the injection sites. The microcatheter
technique using the suprachoroidal space has the potential of
being able to deliver virus at multiple sites through a single incision
port in the eye, which may result in a greater overall area of
transfection that would be beneficial in diseases involving the
whole retina. Furthermore, AAV is being investigated as a
potential delivery agent for anti-angiogenic therapy aimed at
treating choroidal neovascularization [11].
We are currently investigating the effects of virus titer, serotype,
capsid structure, and incubation period on the efficacy of retinal
and choroidal transfection. Additionally, further investigation is
needed to compare the efficacy of transfection between this
method and the standard three-port vitrectomy and subretinal
injection, as well as a more in-depth analysis of potential
complications.
Supporting Information
Figure S1 Illuminated microcatheter tip in the posteri-
or suprachoroidal space, visualized by indirect ophthal-
moscopy.
(TIF)
Figure S2 Schematic of iScience 250A microcannula
(top) and introduction of the microcatheter through the
sclerotomy into the suprachoroidal space and advanced
towards the optic disc (bottom). Photographs courtesy of
iScience Interventional.
(TIF)
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